Biofelt is a new absorbable scaffold for implant devices in orthopedics, cardiology and general surgery being introduced by Biomedical Structures (BMS), based in Warwick, Rhode Island, USA, following its 2011 acquisition of medical textile manufacturer Concordia Medical.

The structure of Biofely provides a fibrous matrix platform which enables natural tissue in-growth in surgical applications.

The three dimensional nonwoven has a very high surface area and void volume designed to promote natural cell adhesion and regeneration.

Produced from PGA (polyglycolic acid), PLLA (poly l lactic acid) and copolymers such as PLGA (co-polylactic acid/glycolic acid), Biofelt can be used as a component of medical devices or surgical systems with the benefit of bio-absorbability.

“Biofelt is a terrific example of how traditional tissue engineering technology and materials can be used in more innovative ways across medical device sectors,” said Dean Tulumaris, president and CEO of BMS. “We dedicate tremendous resources to the engineering of customised solutions for the most difficult and novel device challenges.”

Biofelt is custom-engineered for individual device requirements and is available in a wide array of densities and thicknesses to allow for application-specific performance. Proven in cardiovascular, orthopedic and urological tissue regeneration applications, it can be employed in everything from internal wound management to hemostasis. It can be produced as flat sheets, discs, tubes and a variety of other geometric shapes with an absorption profile from anywhere from less than 30 days to a year.